COMPASS PATHWAYS PLC - AMERICAN DEPOSITORY SHARES

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

08 May 2024 06:45:00 By Nasdaq GlobeNewswire

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

08 May 2024 06:30:00 By Nasdaq GlobeNewswire

Compass Pathways to announce first quarter financial results on May 8, 2024

03 May 2024 16:58:08 By Nasdaq GlobeNewswire

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

02 May 2024 06:30:00 By Nasdaq GlobeNewswire

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

29 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference

01 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

28 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights 

29 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Pathways to participate in upcoming TD Cowen investor conference

26 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024

22 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Compass Pathways to participate in upcoming Oppenheimer investor conference

31 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

16 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

05 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

19 Dec 2023 16:05:00 By Nasdaq GlobeNewswire

Compass Pathways appoints Teri Loxam as Chief Financial Officer

07 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry

06 Dec 2023 16:00:09 By Nasdaq GlobeNewswire

Compass Pathways to participate in upcoming Evercore investor conference

24 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

15 Nov 2023 04:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways announces CFO transition

26 Oct 2023 08:00:00 By Nasdaq GlobeNewswire